Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (19420)	3/22/2006 10:58:58 PM
From: zeta1961	Respond to of 52153

<placebo trials, ethics, law>, in the perfect world, yes, we shouldn't need the law to police this kind of medical practice..to use the rcc trial as an example, can one safely assume the placebo patients were made aware of ifn/il2 options and chose to reject them, therefore making this study fine, ethically?..I don't know the answer to that The issue of placebo in 1956 was put in there when it was initially drafted a few years ago..my concern, quite frankly, is more about full transparency of clinical trials available by the various cancer centers..competition for patients is at an all time high..the different groups are not in a rush to have their patient cross to another one..yet, if the patient initiates it, they will help[in my experience].. Elisabeth